PE20181530A1 - Vacuna de virus sincitial respiratorio - Google Patents
Vacuna de virus sincitial respiratorioInfo
- Publication number
- PE20181530A1 PE20181530A1 PE2018000599A PE2018000599A PE20181530A1 PE 20181530 A1 PE20181530 A1 PE 20181530A1 PE 2018000599 A PE2018000599 A PE 2018000599A PE 2018000599 A PE2018000599 A PE 2018000599A PE 20181530 A1 PE20181530 A1 PE 20181530A1
- Authority
- PE
- Peru
- Prior art keywords
- virus vaccine
- respiratory syncitial
- syncitial virus
- vaccines
- respiratory
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- 229920002477 rna polymer Polymers 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripcion se refiere a vacunas de acido ribonucleico (ARN) de virus sincitial respiratorio (RSV), asi como a metodos para utilizar las vacunas y a composiciones que comprenden las vacunas
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245031P | 2015-10-22 | 2015-10-22 | |
US201562245208P | 2015-10-22 | 2015-10-22 | |
US201562247563P | 2015-10-28 | 2015-10-28 | |
US201562248250P | 2015-10-29 | 2015-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20181530A1 true PE20181530A1 (es) | 2018-09-26 |
Family
ID=58558153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000599A PE20181530A1 (es) | 2015-10-22 | 2016-10-21 | Vacuna de virus sincitial respiratorio |
Country Status (20)
Country | Link |
---|---|
US (2) | US20180271970A1 (es) |
EP (1) | EP3365008A4 (es) |
JP (3) | JP2019501208A (es) |
KR (1) | KR20180096592A (es) |
CN (1) | CN108472354A (es) |
AU (1) | AU2016341311B2 (es) |
BR (1) | BR112018008102A2 (es) |
CA (1) | CA3002820A1 (es) |
CL (1) | CL2018001053A1 (es) |
CO (1) | CO2018005229A2 (es) |
EA (1) | EA201891000A1 (es) |
IL (1) | IL258831A (es) |
MA (1) | MA46317A (es) |
MX (1) | MX2018004917A (es) |
PE (1) | PE20181530A1 (es) |
PH (1) | PH12018500856A1 (es) |
SG (2) | SG11201803363YA (es) |
TN (1) | TN2018000154A1 (es) |
TW (1) | TW201729836A (es) |
WO (1) | WO2017070622A1 (es) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
CA2946751A1 (en) | 2014-04-23 | 2015-10-29 | Modernatx, Inc. | Nucleic acid vaccines |
WO2017015463A2 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
MA47016A (fr) | 2015-10-22 | 2018-08-29 | Modernatx Inc | Vaccins contre les virus respiratoires |
TW201729838A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗 |
AU2016366978B2 (en) | 2015-12-10 | 2022-07-28 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
WO2017191264A1 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
EP3458107B1 (en) | 2016-05-18 | 2024-03-13 | ModernaTX, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
BR112018073683A2 (pt) | 2016-05-18 | 2019-02-26 | Modernatx, Inc. | polinucleotídeos codificadores de relaxina |
CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
EP3609534A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
JP7408098B2 (ja) | 2017-08-18 | 2024-01-05 | モデルナティエックス インコーポレイテッド | Rnaポリメラーゼバリアント |
MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
MA52074A (fr) | 2018-03-19 | 2021-01-27 | Bayer Healthcare Llc | Nouveaux systèmes d'endonucléase à arn programmable et leurs utilisations |
WO2019191623A1 (en) | 2018-03-30 | 2019-10-03 | Georgia State University Research Foundation, Inc. | Respiratory syncytial virus (rsv) vaccines |
US20210170017A1 (en) | 2018-04-17 | 2021-06-10 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
BR112021000965A2 (pt) * | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
KR102725189B1 (ko) * | 2018-11-01 | 2024-10-31 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
EP3887513A2 (en) | 2018-11-28 | 2021-10-06 | CRISPR Therapeutics AG | Optimized mrna encoding cas9 for use in lnps |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
WO2020172239A1 (en) | 2019-02-20 | 2020-08-27 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
AU2020229815A1 (en) * | 2019-02-28 | 2021-09-16 | Novavax, Inc. | Methods for preventing disease or disorder caused by RSV infection |
WO2020186059A2 (en) | 2019-03-12 | 2020-09-17 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
CN114269373A (zh) * | 2019-04-02 | 2022-04-01 | 赛诺菲 | 抗原性多聚呼吸道合胞病毒多肽 |
CN110638759A (zh) * | 2019-10-29 | 2020-01-03 | 珠海丽凡达生物技术有限公司 | 一种用于体外转染和体内递送mRNA的制剂 |
CA3169664A1 (en) * | 2020-01-30 | 2021-08-05 | Modernatx, Inc. | Respiratory virus immunizing compositions |
JP2021185136A (ja) | 2020-04-22 | 2021-12-09 | ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | コロナウイルスワクチン |
CN116322758A (zh) | 2020-05-29 | 2023-06-23 | 库尔维科欧洲股份公司 | 基于核酸的组合疫苗 |
CN115803333A (zh) | 2020-07-02 | 2023-03-14 | 生命技术公司 | 三核苷酸帽类似物、其制备和用途 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN111973563B (zh) * | 2020-09-02 | 2022-06-28 | 崔海港 | 一种鼠李糖脂冻干粉制剂及其制备方法和应用 |
US11771652B2 (en) * | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
IL308896A (en) | 2021-06-11 | 2024-01-01 | Bayer Ag | Type v rna programmable endonuclease systems |
MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
US20250084391A1 (en) | 2021-12-23 | 2025-03-13 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
EP4531902A1 (en) | 2022-05-25 | 2025-04-09 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
EP4536818A1 (en) | 2022-06-10 | 2025-04-16 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
TW202440914A (zh) | 2022-12-13 | 2024-10-16 | 美商藍岩醫療公司 | 工程化之第v型rna可程式化核酸內切酶及其用途 |
US12239701B2 (en) | 2023-02-03 | 2025-03-04 | Vernagen, LLC | Respiratory syncytial virus mRNA vaccine |
CN116286672B (zh) * | 2023-02-07 | 2025-01-28 | 金宇保灵生物药品有限公司 | 一种口蹄疫病毒及其应用 |
CN119137160A (zh) * | 2023-03-02 | 2024-12-13 | 苏州艾博生物科技有限公司 | 呼吸道合胞病毒(rsv)的核酸疫苗 |
WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
WO2024194153A1 (en) * | 2023-03-17 | 2024-09-26 | Glaxosmithkline Biologicals Sa | Rsv-f-encoding nucleic acids |
WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
WO2024260359A1 (zh) * | 2023-06-20 | 2024-12-26 | 石药集团巨石生物制药有限公司 | 一种抵抗呼吸道合胞病毒的mRNA疫苗及其制备方法 |
WO2024259624A1 (en) * | 2023-06-21 | 2024-12-26 | Shenzhen Genius Biotech Service Co. Ltd | A modified rsv f protein, a nanoparticle, a composition and a vaccine against respiratory syncytial virus infection |
CN119490569A (zh) * | 2023-08-16 | 2025-02-21 | 深圳瑞吉生物科技有限公司 | 呼吸道合胞病毒抗原性多肽、核酸、疫苗及其应用 |
CN117487823B (zh) * | 2023-09-28 | 2024-10-29 | 怡道生物科技(苏州)有限公司 | 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用 |
WO2025076291A1 (en) | 2023-10-06 | 2025-04-10 | Bluerock Therapeutics Lp | Engineered type v rna programmable endonucleases and their uses |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
EP1392341B1 (de) | 2001-06-05 | 2005-03-30 | Curevac GmbH | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
EP1412065A2 (en) | 2001-07-27 | 2004-04-28 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
US20060051424A1 (en) | 2001-10-03 | 2006-03-09 | Johns Hopkins University | Compositions of oral gene therapy and methods of using same |
AU2003217531A1 (en) | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
US8957034B2 (en) | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
CA2590098C (en) | 2004-12-10 | 2015-03-31 | Justin Hanes | Functionalized poly (ether-anhydride) block copolymers |
AU2006231452B2 (en) | 2005-04-01 | 2011-05-26 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
WO2006110776A2 (en) | 2005-04-12 | 2006-10-19 | Nektar Therapeutics Al, Corporation | Polyethylene glycol cojugates of antimicrobial agents |
JP5081820B2 (ja) | 2005-06-16 | 2012-11-28 | ネクター セラピューティックス | 分解性結合を有する複合体と該複合体の調製に有益なポリマー試薬 |
CN103030801B (zh) | 2006-02-21 | 2015-07-22 | 尼克塔治疗公司 | 嵌段可降解聚合物及由其制备的轭合物 |
WO2007133807A2 (en) | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
JP2010502713A (ja) | 2006-09-08 | 2010-01-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液を通る輸送を増強するための組成物および方法 |
EP2120859B1 (en) | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
CA2702305C (en) | 2007-03-30 | 2015-07-21 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
ES2654533T3 (es) | 2008-06-16 | 2018-02-14 | Pfizer Inc. | Procedimientos para la preparación de copolímeros dibloque funcionalizados con un agente de direccionamiento para su uso en la fabricación de nanopartículas terapéuticas |
US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
JP2012501966A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法 |
WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
PL2355851T3 (pl) * | 2008-11-10 | 2018-08-31 | Arbutus Biopharma Corporation | Nowe lipidy i kompozycje do dostarczania środków terapeutycznych |
JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
US20120101148A1 (en) * | 2009-01-29 | 2012-04-26 | Alnylam Pharmaceuticals, Inc. | lipid formulation |
JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
WO2011140627A1 (en) | 2009-11-04 | 2011-11-17 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
EP2512459A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME | |
ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
US20130101609A1 (en) | 2010-01-24 | 2013-04-25 | Novartis Ag | Irradiated biodegradable polymer microparticles |
US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
US20130196948A1 (en) | 2010-06-25 | 2013-08-01 | Massachusetts Insitute Of Technology | Polymers for biomaterials and therapeutics |
EP2590676B1 (en) * | 2010-07-06 | 2016-08-17 | GlaxoSmithKline Biologicals SA | Virion-like delivery particles for self-replicating rna molecules |
MX2013000164A (es) * | 2010-07-06 | 2013-03-05 | Novartis Ag | Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn. |
DK2591114T3 (en) * | 2010-07-06 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
EP2629760A4 (en) | 2010-10-22 | 2014-04-02 | Bind Therapeutics Inc | THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT |
CA2816977C (en) | 2010-11-05 | 2019-10-29 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
WO2012131106A1 (en) | 2011-03-31 | 2012-10-04 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
EP2691079B1 (en) | 2011-03-31 | 2020-06-24 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
EP2729124B1 (en) * | 2011-07-06 | 2018-10-24 | GlaxoSmithKline Biologicals SA | Cationic oil-in-water emulsions |
US20140141070A1 (en) * | 2011-07-06 | 2014-05-22 | Andrew Geall | Liposomes having useful n:p ratio for delivery of rna molecules |
CN103732211B (zh) | 2011-07-21 | 2017-03-01 | 禾大国际股份公开有限公司 | 支化的聚醚‑聚酰胺嵌段共聚物及其制造与使用方法 |
AU2012300476B2 (en) | 2011-08-26 | 2016-03-24 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
JP2014527071A (ja) | 2011-08-31 | 2014-10-09 | マリンクロッド エルエルシー | H−ホスホネートによるナノ粒子pegの改変 |
US20150017245A1 (en) | 2011-09-22 | 2015-01-15 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
EP3597644B1 (en) | 2011-10-18 | 2021-09-29 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
US9415020B2 (en) | 2012-01-19 | 2016-08-16 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
JP6182159B2 (ja) | 2012-02-03 | 2017-08-16 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | フェノール性単量体から誘導された高分子生体材料およびその医療用途 |
US20150337068A1 (en) | 2012-02-10 | 2015-11-26 | Karl K Berggren | Preparation, purification and use of high-x diblock copolymers |
AU2013243954A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
MX2014015041A (es) * | 2012-06-08 | 2015-06-17 | Shire Human Genetic Therapies | Administración pulmonar de arnm a células objetivo no pulmonares. |
EP3628335B1 (en) * | 2012-12-07 | 2023-11-08 | Translate Bio, Inc. | Lipidic nanoparticles for mrna delivery in the lungs |
MX385818B (es) * | 2013-03-13 | 2025-03-18 | Us Health | Proteínas f de rsv de prefusión y su uso. |
US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
HUE055044T2 (hu) * | 2013-03-14 | 2021-10-28 | Translate Bio Inc | MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
WO2014144196A1 (en) * | 2013-03-15 | 2014-09-18 | Shire Human Genetic Therapies, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
US10125172B2 (en) * | 2013-07-25 | 2018-11-13 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
BR112016003361A2 (pt) * | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
-
2016
- 2016-10-21 EA EA201891000A patent/EA201891000A1/ru unknown
- 2016-10-21 PE PE2018000599A patent/PE20181530A1/es unknown
- 2016-10-21 TW TW105134193A patent/TW201729836A/zh unknown
- 2016-10-21 CN CN201680075062.6A patent/CN108472354A/zh active Pending
- 2016-10-21 WO PCT/US2016/058321 patent/WO2017070622A1/en active Application Filing
- 2016-10-21 KR KR1020187014339A patent/KR20180096592A/ko not_active Withdrawn
- 2016-10-21 SG SG11201803363YA patent/SG11201803363YA/en unknown
- 2016-10-21 TN TNP/2018/000154A patent/TN2018000154A1/en unknown
- 2016-10-21 SG SG10201914006UA patent/SG10201914006UA/en unknown
- 2016-10-21 AU AU2016341311A patent/AU2016341311B2/en not_active Expired - Fee Related
- 2016-10-21 US US15/767,613 patent/US20180271970A1/en not_active Abandoned
- 2016-10-21 CA CA3002820A patent/CA3002820A1/en active Pending
- 2016-10-21 MX MX2018004917A patent/MX2018004917A/es unknown
- 2016-10-21 EP EP16858402.7A patent/EP3365008A4/en active Pending
- 2016-10-21 BR BR112018008102A patent/BR112018008102A2/pt not_active Application Discontinuation
- 2016-10-21 MA MA046317A patent/MA46317A/fr unknown
- 2016-10-21 JP JP2018541089A patent/JP2019501208A/ja active Pending
-
2018
- 2018-04-20 PH PH12018500856A patent/PH12018500856A1/en unknown
- 2018-04-20 CL CL2018001053A patent/CL2018001053A1/es unknown
- 2018-04-22 IL IL258831A patent/IL258831A/en unknown
- 2018-05-18 CO CONC2018/0005229A patent/CO2018005229A2/es unknown
-
2022
- 2022-10-27 JP JP2022172576A patent/JP2023015151A/ja active Pending
-
2023
- 2023-05-10 US US18/314,980 patent/US20230390379A1/en active Pending
-
2024
- 2024-12-24 JP JP2024227631A patent/JP2025041835A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG10201914006UA (en) | 2020-03-30 |
AU2016341311B2 (en) | 2023-11-16 |
AU2016341311A1 (en) | 2018-06-07 |
CL2018001053A1 (es) | 2018-10-19 |
JP2023015151A (ja) | 2023-01-31 |
TN2018000154A1 (en) | 2019-10-04 |
EP3365008A1 (en) | 2018-08-29 |
MA46317A (fr) | 2019-08-07 |
US20230390379A1 (en) | 2023-12-07 |
EA201891000A1 (ru) | 2018-12-28 |
SG11201803363YA (en) | 2018-05-30 |
PH12018500856A1 (en) | 2018-10-29 |
JP2019501208A (ja) | 2019-01-17 |
KR20180096592A (ko) | 2018-08-29 |
BR112018008102A2 (pt) | 2018-11-06 |
EP3365008A4 (en) | 2019-08-07 |
CA3002820A1 (en) | 2017-04-27 |
JP2025041835A (ja) | 2025-03-26 |
US20180271970A1 (en) | 2018-09-27 |
WO2017070622A1 (en) | 2017-04-27 |
CN108472354A (zh) | 2018-08-31 |
CO2018005229A2 (es) | 2018-11-30 |
TW201729836A (zh) | 2017-09-01 |
MX2018004917A (es) | 2019-04-01 |
IL258831A (en) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181530A1 (es) | Vacuna de virus sincitial respiratorio | |
PE20181531A1 (es) | Vacuna del virus herpes simple | |
CY1125368T1 (el) | Εμβολια κατα των ιων του αναπνευστικου συστηματος | |
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
NI201700128A (es) | Composiciones de acido obeticolico y metodos de uso. | |
BR112016024644A2 (pt) | vacinas de ácido nucleico | |
CR20150370A (es) | Compuestos antivirales | |
CL2015001442A1 (es) | Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico. | |
MX2021010060A (es) | Produccion de virus en huevos aviares. | |
MX2016010263A (es) | Composiciones estabilizadas de silicato y su uso como composiciones antitranspirantes. | |
BR112014026149A2 (pt) | método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo. | |
BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
GT201600066A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
PH12016502229A1 (en) | Process for preparing phosphorus-containing cyanohydrins | |
UY37193A (es) | Nuevos compuestos antivíricos | |
MX2017006200A (es) | Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico. | |
CO2017010018A2 (es) | Derivados de ácido (s)-2’-vinil-abscísico | |
BR112015023591A2 (pt) | processo para a preparação de 4-amino-1-((ls,4r,5s)-2-fluoro-4,5-di-hidróxi-3-hidroximetil-ciclopent-2-enii)-1h-pirimidin-2-ona | |
AR106464A1 (es) | Vacuna de virus sincitial respiratorio | |
AR102161A1 (es) | Procesos para preparar 2,5-diclorofenol | |
GT201500116A (es) | Mètodo para preparar derivados de feniloximetil-nitro-imidazol y su uso del mismo |